IMMUNOCORE HOLDINGS PLC-ADR
Immunocore Holdings plc discovers and develops novel T cell receptor based biological drugs to treat cancer and infectious diseases.
Stock Performance Snapshot
Financial Health
Immunocore is performing well with strong revenue and impressive profit margins from its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMCR
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
TCR Immunotherapy Focus
Immunocore’s unique T‑cell receptor approach aims to broaden immune targeting of tumours, though clinical results and uptake can vary.
Clinical Milestones Matter
Trial readouts and regulatory decisions tend to move the share price significantly, offering potential upside alongside binary risk.
Commercial & Partnership Drivers
Revenue and scale depend on market adoption and collaborations; partnerships can de‑risk development but outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
